Hemab Therapeutics Holdings, Inc. 8-K

What Happened Hemab Therapeutics Holdings, Inc. announced on May 4, 2026 that it closed its initial public offering (IPO) and filed a Restated Certificate of Incorporation and Amended and Restated Bylaws effective upon the closing. The IPO sold 19,262,500 shares of common stock at $18.00 per share (including the full exercise of the underwriters’ option for 2,512,500 additional shares), producing gross proceeds of approximately $346.7 million before underwriting discounts, commissions and offering expenses.

Key Details

• IPO close date: May 4, 2026; shares sold: 19,262,500; public offering price: $18.00/share.
• Gross proceeds to the company: $346.7 million (pre-fees and expenses).
• Restated Certificate changes include: authorized common stock increased to 400,000,000 shares; elimination of prior preferred series; authorization of 5,000,000 undesignated preferred shares.
• Corporate governance changes: establishes a three-class staggered board (three-year terms); directors removable only for cause by holders of at least 75% voting power; vacancies filled by existing directors only; stockholder written consents and special meeting rights eliminated.
• Forum selection provisions: Delaware Court of Chancery designated as exclusive forum for internal corporate claims; federal courts designated for other stockholder claims (including Securities Act and Exchange Act claims) unless the company consents otherwise.

Why It Matters This 8-K confirms Hemab’s transition to a public company with significant capital raised from the IPO and important corporate governance changes that can affect shareholder rights and litigation venues. Investors should note the large authorized share count and the board’s classified structure and heightened removal threshold, as these provisions can influence shareholder influence over board composition and corporate control. The forum selection clauses also steer where certain disputes must be litigated, which can affect legal strategy and costs.